Evidence map›Paper›PMID 40876356›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2025

In vitro screening of the open-access Pandemic Response Box reveals ESI-09 as a compound with activity against Echinococcus multilocularis.

Pascal Zumstein, Anissa Bartetzko, Marc Kaethner, Laura Vetter, Andrew Hemphill, Trix Zumkehr, Benoît Laleu, Matías Preza, Britta Lundström-Stadelmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pascal ZumsteinInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
Anissa BartetzkoInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Marc KaethnerInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Laura VetterInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Andrew HemphillInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Trix ZumkehrInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Benoît LaleuMMV Medicines for Malaria Venture, ICC, Route de Pré-Bois 20, 1215, Geneva, Switzerland.
Matías PrezaInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland. Electronic address: matias.preza@unibe.ch.
Britta Lundström-StadelmannInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland; Multidisciplinary Center for Infectious Diseases, University of Bern, Bern, Switzerland. Electronic address: britta.lundstroem@unibe.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alveolar echinococcosis (AE) is a life-threatening disease caused by the metacestode stage of the fox tapeworm Echinococcus multilocularis, primarily in the liver. Current drug treatments rely on benzimidazoles, which are not parasiticidal, requiring life-long therapy with significant side effects. Therefore, novel drug treatments are urgently needed. Drug repurposing offers a strategy to identify novel therapies against the neglected disease AE. We report on the in vitro screening of the Pandemic Response Box, an open-access compound library composed of 400 drug-like molecules assembled by Medicines for Malaria Venture (MMV) and the Drugs for Neglected Disease Initiative (DNDi), against E. multilocularis. An overview screen at 10 μM using the metacestode vesicle damage-marker release assay (based on release of phosphoglucose isomerase, PGI) and metacestode vesicle viability assay (based on ATP measurement) identified 37 active compounds. Reassessment in triplicates resulted in five active compounds (alexidine, carbendazim, ESI-09, MMV1581545, oxfendazole) displaying anti-metacestode activity. The parasiticidal activity of these five compounds was evaluated by ATP measurement in germinal layer cells. One compound, ESI-09, acted specifically against E. multilocularis (IC

Indexed as

AnthelminticsEchinococcus multilocularisAnimalsDrug Evaluation, PreclinicalDrug RepositioningEchinococcosisHumansAnthelminticsAlveolar echinococcosisDNDiDrug repurposingEchinococcus mutlilocularisMitochondrial uncouplerMMV

Identifiers

PMID40876356
PMCPMC12410356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.